



NEW BUSINESS MODELS FOR INNOVATION AND ACCESS TO MEDICINES

Researchers

Principal Investigator (PI): Suerie Moon
Researchers: Adrián Alonso Ruiz, Marcela
Vieira, Kaitlin Large, Yiqi Liu, Iulia Slovenski

Additional information

Funding Organization: Swiss National
Science Foundation's PRIMA programme
(SNF), Open Society University Network
Budget: CHF 1,730,875

Keywords: access to medicines, research
and development (R&D), technological
innovation, business models, global
governance

Description

The objective of this project is to deepen understanding of the political, economic, scientific and organisational factors required to implement new models of medicines R&D that will deliver both innovation and globally accessible medicines. The project investigates the characterisation, history and scope of "alternative innovation models", and identifies what led to their creation as alternatives to the status quo. The project also identifies the factors that shape whether or not such models survive - or even thrive - within the system, and examine the possibilities they can expand beyond their particular niches. As the project entered its last year, it has started to consolidate its findings. The project has developed conceptual frameworks to define and draw distinctions between traditional and alternative innovation models, and how they emerge within a complex, adaptive innovation system. Through a mapping of existing examples of alternative innovation

models and a series of three case studies, the project assessed across four different areas (i.e., rare diseases, antimicrobial resistance, pandemic preparedness and neglected diseases) the feasibility and effectiveness of these models, exploring impact, structural strengths and weaknesses, and implications regarding who does or does not benefit from each model. The project has a global scope, including not only initiatives based in traditional centres of pharmaceutical innovation but also initiatives in the Global South, assessing the extent to which such initiatives represent alternative approaches to R&D, and the implications for

global access. To assess this, in 2021, the project expanded to include a research collaboration with James P. Grant School of Public Health at BRAC University (Bangladesh) and Universidad de los Andes (ANDES, Colombia). This research collaboration was supported by the Open Society University Network (OSUN) / Open Society Foundations (OSF).

